{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:02:17Z","timestamp":1791324137387,"version":"4.3.1"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/jcp.0b013e3182549259","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T05:43:35Z","timestamp":1335505415000},"page":"309-316","source":"Crossref","is-referenced-by-count":179,"title":["Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents"],"prefix":"10.1097","volume":"32","author":[{"given":"David","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bonnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":". National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-9-72","article-title":". Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data.","volume":"9","author":"Acquaviva","year":"2009","journal-title":"BMC Psychiatry"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004583-200212000-00015","article-title":". Effects of development on olanzapine-associated adverse events.","volume":"41","author":"Woods","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":". Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neurenf.2009.09.004","article-title":". Surveillance of metabolic syndrome, hyperprolactinemia and cardiac side effects in children and adolescent treated with antipsychotic. Actuality and recommendations.","volume":"58","author":"Bonnot","year":"2010","journal-title":"Neuropsychiatr Enfance Adolesc"},{"key":"R8-2-20210128","first-page":"5","article-title":"Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned Psychother Psychosom.","volume":"76","author":"Cohen","year":"2007","journal-title":""},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":". Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0895-4356(92)90085-2","article-title":". Incorporating variations in the quality of individual randomized trials into meta-analysis.","volume":"45","author":"Detsky","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"7521","key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence.","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":". WinBUGSa Bayesian modelling framework: concepts, structure, and extensibility.","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"R15-2-20210128","first-page":"174","article-title":"Explaining the Gibbs sampler.","volume":"167-","author":"Casella","year":"1992","journal-title":"Am Stat"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1109\/TPAMI.1984.4767596","article-title":"Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images.","volume":"6","author":"German","year":"1984","journal-title":"IEEE Trans Pattern Anal Machine Intell"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1063\/1.1699114","article-title":". Equation of state calculations by fast computing machines.","volume":"21","author":"Metropolis","year":"1953","journal-title":"J Chem Physics"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: a package for running WinBUGS from R.","volume":"12","author":"Sturtz","year":"2005","journal-title":"J Stat Software"},{"key":"R20-2-20210128","first-page":"7","article-title":". CODA: convergence diagnosis and output analysis for MCMC.","volume":"6","author":"Plummer","year":"2006","journal-title":"R News"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-006-0602-7","article-title":". Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.","volume":"114","author":"Fleischhaker","year":"2007","journal-title":"J Neural Transm"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":". Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":". A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":". Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.","volume":"70","author":"Findling","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":". Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.","volume":"11","author":"Haas","year":"2009","journal-title":"Bipolar Disord"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":". A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.","volume":"19","author":"Haas","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":". Olanzapine versus placebo in the treatment of adolescents with bipolar mania.","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R28-2-20210128","first-page":"157","article-title":"Raffin-Viard M, et al..","volume":"21","author":"Bonnot","year":"2011","journal-title":"Children and adolescents with severe mental illness need Vitamin D supplementation regardless of disease or treatment J Child Adolesc Psychopharmacol"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":". A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":". A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":". Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1399-5618.2010.00797.x","article-title":". Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.","volume":"12","author":"Moreno","year":"2010","journal-title":"Bipolar Disord"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":". Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R34-2-20210128","first-page":"583","article-title":". Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.","volume":"49","author":"Findling","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-5618.2010.00850.x","article-title":". Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder.","volume":"12","author":"Pavuluri","year":"2010","journal-title":"Bipolar Disord"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/cap.2009.0042","article-title":". Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.","volume":"19","author":"Wozniak","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.08m04726","article-title":". Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficithyperactivity disorder: a pilot randomized clinical trial.","volume":"70","author":"Tramontina","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","article-title":". Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.","volume":"194","author":"Haas","year":"2009","journal-title":"Br J Psychiatry"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopsych.2005.03.019","article-title":". Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.","volume":"58","author":"Biederman","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":". Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.chi.0000194567.63289.97","article-title":". A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.","volume":"45","author":"DelBello","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-5618.2009.00728.x","article-title":". A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.","volume":"11","author":"DelBello","year":"2009","journal-title":"Bipolar Disord"},{"issue":"347","key":"R46-2-20210128","first-page":"314","article-title":"Risperidone in children with autism and serious behavioral problems.","year":"2002","journal-title":"N Engl J Med"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":". Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":". Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":". Clozapine and high-dose olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.chi.0000170552.15798.dd","article-title":". Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study.","volume":"44","author":"Sporn","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":". Ziprasidone treatment of children and adolescents with Tourettes syndrome: a pilot study.","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":". Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.","volume":"41","author":"Snyder","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archpsyc.1996.01830120020005","article-title":". Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison.","volume":"53","author":"Kumra","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/cap.2004.14.350","article-title":". A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents.","volume":"14","author":"Saito","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","article-title":". A double-blind pilot study of risperidone in the treatment of conduct disorder.","volume":"39","author":"Findling","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R56-2-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/cap.2008.008","article-title":". Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.","volume":"18","author":"DelBello","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R57-2-20210128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","article-title":". Risperidone versus clonidine in the treatment of children and adolescents with Tourettes syndrome.","volume":"41","author":"Gaffney","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R58-2-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.16.665","article-title":". The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).","volume":"16","author":"Barzman","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R59-2-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":". A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.","volume":"62","author":"Buitelaar","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R60-2-20210128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":". Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison.","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R61-2-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2007.0123","article-title":". A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.","volume":"18","author":"Jensen","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R62-2-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.16.393","article-title":". An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.","volume":"16","author":"Mozes","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182549259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:59:55Z","timestamp":1620943195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201206000-00002"}},"subtitle":["A Bayesian Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182549259","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948532.793453650","asserted-by":"object"}]},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}